1
|
Rasetti-Escargueil C, Palea S. Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic Applications. Toxins (Basel) 2024; 16:261. [PMID: 38922155 PMCID: PMC11209287 DOI: 10.3390/toxins16060261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2024] [Revised: 05/26/2024] [Accepted: 05/27/2024] [Indexed: 06/27/2024] Open
Abstract
Botulinum neurotoxins (BoNTs) have been used for almost half a century in the treatment of excessive muscle contractility. BoNTs are routinely used to treat movement disorders such as cervical dystonia, spastic conditions, blepharospasm, and hyperhidrosis, as well as for cosmetic purposes. In addition to the conventional indications, the use of BoNTs to reduce pain has gained increased recognition, giving rise to an increasing number of indications in disorders associated with chronic pain. Furthermore, BoNT-derived formulations are benefiting a much wider range of patients suffering from overactive bladder, erectile dysfunction, arthropathy, neuropathic pain, and cancer. BoNTs are categorised into seven toxinotypes, two of which are in clinical use, and each toxinotype is divided into multiple subtypes. With the development of bioinformatic tools, new BoNT-like toxins have been identified in non-Clostridial organisms. In addition to the expanding indications of existing formulations, the rich variety of toxinotypes or subtypes in the wild-type BoNTs associated with new BoNT-like toxins expand the BoNT superfamily, forming the basis on which to develop new BoNT-based therapeutics as well as research tools. An overview of the diversity of the BoNT family along with their conventional therapeutic uses is presented in this review followed by the engineering and formulation opportunities opening avenues in therapy.
Collapse
Affiliation(s)
| | - Stefano Palea
- Humana Biosciences-Prologue Biotech, 516 Rue Pierre et Marie Curie, 31670 Labège, France;
| |
Collapse
|
2
|
Popova TV, Krumkacheva OA, Burmakova AS, Spitsyna AS, Zakharova OD, Lisitskiy VA, Kirilyuk IA, Silnikov VN, Bowman MK, Bagryanskaya EG, Godovikova TS. Protein modification by thiolactone homocysteine chemistry: a multifunctionalized human serum albumin theranostic. RSC Med Chem 2020; 11:1314-1325. [PMID: 34085043 PMCID: PMC8126878 DOI: 10.1039/c9md00516a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2019] [Accepted: 03/23/2020] [Indexed: 01/15/2023] Open
Abstract
As the most abundant protein with a variety of physiological functions, albumin has been used extensively for the delivery of therapeutic molecules. Thiolactone chemistry provides a powerful tool to prepare spin-labeled albumin-based multimodal imaging probes and therapeutic agents. We report the synthesis of a tamoxifen homocysteine thiolactone derivative and its use in thiol-'click' chemistry to prepare multi-functionalized serum albumin. The released sulfhydryl group of the homocysteine functional handle was labeled with a nitroxide reagent to prepare a spin-labeled albumin-tamoxifen conjugate confirmed by MALDI-TOF-MS, EPR spectroscopy, UV-vis and fluorescent emission spectra. This is the basis for a novel multimodal tamoxifen-albumin theranostic with a significant (dose-dependent) inhibitory effect on the proliferation of malignant cells. The response of human glioblastoma multiforme T98G cells and breast cancer MCF-7 cells to tamoxifen and its albumin conjugates was different in tumor cells with different expression level of ERα in our experiments. These results provide further impetus to develop a serum protein for delivery of tamoxifen to cancer cells.
Collapse
Affiliation(s)
- Tatyana V Popova
- Institute of Chemical Biology and Fundamental Medicine SB RAS 630090 Novosibirsk Russia
- Novosibirsk State University 630090 Novosibirsk Russia
| | - Olesya A Krumkacheva
- Novosibirsk State University 630090 Novosibirsk Russia
- International Tomography Center SB RAS 630090 Novosibirsk Russia
| | - Anna S Burmakova
- Institute of Chemical Biology and Fundamental Medicine SB RAS 630090 Novosibirsk Russia
- Novosibirsk State University 630090 Novosibirsk Russia
| | - Anna S Spitsyna
- Novosibirsk State University 630090 Novosibirsk Russia
- Novosibirsk Institute of Organic Chemistry SB RAS 630090 Novosibirsk Russia
| | - Olga D Zakharova
- Institute of Chemical Biology and Fundamental Medicine SB RAS 630090 Novosibirsk Russia
| | - Vladimir A Lisitskiy
- Institute of Chemical Biology and Fundamental Medicine SB RAS 630090 Novosibirsk Russia
| | - Igor A Kirilyuk
- Novosibirsk Institute of Organic Chemistry SB RAS 630090 Novosibirsk Russia
| | - Vladimir N Silnikov
- Institute of Chemical Biology and Fundamental Medicine SB RAS 630090 Novosibirsk Russia
| | - Michael K Bowman
- Novosibirsk Institute of Organic Chemistry SB RAS 630090 Novosibirsk Russia
- University of Alabama Tuscaloosa Alabama 35487-0336 USA
| | - Elena G Bagryanskaya
- Novosibirsk State University 630090 Novosibirsk Russia
- Novosibirsk Institute of Organic Chemistry SB RAS 630090 Novosibirsk Russia
| | - Tatyana S Godovikova
- Institute of Chemical Biology and Fundamental Medicine SB RAS 630090 Novosibirsk Russia
| |
Collapse
|
3
|
Yadirgi G, Stickings P, Rajagopal S, Liu Y, Sesardic D. Immuno-detection of cleaved SNAP-25 from differentiated mouse embryonic stem cells provides a sensitive assay for determination of botulinum A toxin and antitoxin potency. J Immunol Methods 2017; 451:90-99. [PMID: 28943257 DOI: 10.1016/j.jim.2017.09.007] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2017] [Revised: 09/19/2017] [Accepted: 09/20/2017] [Indexed: 01/12/2023]
Abstract
Botulinum toxin type A is a causative agent of human botulism. Due to high toxicity and ease of production it is classified by the Centres for Disease Control and Prevention as a category A bioterrorism agent. The same serotype, BoNT/A, is also the most widely used in pharmaceutical preparations for treatment of a diverse range of neuromuscular disorders. Traditionally, animals are used to confirm the presence and activity of toxin and to establish neutralizing capabilities of countermeasures in toxin neutralization tests. Cell based assays for BoNT/A have been reported as the most viable alternative to animal models, since they are capable of reflecting all key steps (binding, translocation, internalization and cleavage of intracellular substrate) involved in toxin activity. In this paper we report preliminary development of a simple immunochemical method for specifically detecting BoNT/A cleaved intracellular substrate, SNAP-25, in cell lysates of neurons derived from mouse embryonic stem cells. The assay offers sensitivity of better than 0.1LD50/ml (3fM) which is not matched by other functional assays, including the mouse bioassay, and provides serotype specificity for quantitative detection of BoNT/A and anti-BoNT/A antitoxin. Subject to formal validation, the method described here could potentially be used as a substitute for the mouse bioassay to measure potency and consistency of therapeutic products.
Collapse
Affiliation(s)
- G Yadirgi
- Division of Bacteriology, National Institute for Biological Standards and Control, a center of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK.
| | - P Stickings
- Division of Bacteriology, National Institute for Biological Standards and Control, a center of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK.
| | - S Rajagopal
- Division of Bacteriology, National Institute for Biological Standards and Control, a center of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK.
| | - Y Liu
- Division of Bacteriology, National Institute for Biological Standards and Control, a center of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK.
| | - D Sesardic
- Division of Bacteriology, National Institute for Biological Standards and Control, a center of the Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK.
| |
Collapse
|
4
|
Simon S, Fiebig U, Liu Y, Tierney R, Dano J, Worbs S, Endermann T, Nevers MC, Volland H, Sesardic D, Dorner MB. Recommended Immunological Strategies to Screen for Botulinum Neurotoxin-Containing Samples. Toxins (Basel) 2015; 7:5011-34. [PMID: 26703727 PMCID: PMC4690110 DOI: 10.3390/toxins7124860] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2015] [Revised: 11/03/2015] [Accepted: 11/04/2015] [Indexed: 12/16/2022] Open
Abstract
Botulinum neurotoxins (BoNTs) cause the life-threatening neurological illness botulism in humans and animals and are divided into seven serotypes (BoNT/A–G), of which serotypes A, B, E, and F cause the disease in humans. BoNTs are classified as “category A” bioterrorism threat agents and are relevant in the context of the Biological Weapons Convention. An international proficiency test (PT) was conducted to evaluate detection, quantification and discrimination capabilities of 23 expert laboratories from the health, food and security areas. Here we describe three immunological strategies that proved to be successful for the detection and quantification of BoNT/A, B, and E considering the restricted sample volume (1 mL) distributed. To analyze the samples qualitatively and quantitatively, the first strategy was based on sensitive immunoenzymatic and immunochromatographic assays for fast qualitative and quantitative analyses. In the second approach, a bead-based suspension array was used for screening followed by conventional ELISA for quantification. In the third approach, an ELISA plate format assay was used for serotype specific immunodetection of BoNT-cleaved substrates, detecting the activity of the light chain, rather than the toxin protein. The results provide guidance for further steps in quality assurance and highlight problems to address in the future.
Collapse
Affiliation(s)
- Stéphanie Simon
- CEA Saclay, Institute of Biology and Technologies of Saclay, Laboratory for Immunoanalytical Researches, Gif-sur-Yvette 91191 cedex, France.
| | - Uwe Fiebig
- Biological Toxins, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Seestrasse 10, 13353 Berlin, Germany.
| | - Yvonne Liu
- Division of Bacteriology, National Institute for Biological Standards and Control, a Centre of Medicines & Healthcare Products Regulatory Agency, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK.
| | - Rob Tierney
- Division of Bacteriology, National Institute for Biological Standards and Control, a Centre of Medicines & Healthcare Products Regulatory Agency, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK.
| | - Julie Dano
- CEA Saclay, Institute of Biology and Technologies of Saclay, Laboratory for Immunoanalytical Researches, Gif-sur-Yvette 91191 cedex, France.
| | - Sylvia Worbs
- Biological Toxins, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Seestrasse 10, 13353 Berlin, Germany.
| | - Tanja Endermann
- Biological Toxins, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Seestrasse 10, 13353 Berlin, Germany.
| | - Marie-Claire Nevers
- CEA Saclay, Institute of Biology and Technologies of Saclay, Laboratory for Immunoanalytical Researches, Gif-sur-Yvette 91191 cedex, France.
| | - Hervé Volland
- CEA Saclay, Institute of Biology and Technologies of Saclay, Laboratory for Immunoanalytical Researches, Gif-sur-Yvette 91191 cedex, France.
| | - Dorothea Sesardic
- Division of Bacteriology, National Institute for Biological Standards and Control, a Centre of Medicines & Healthcare Products Regulatory Agency, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK.
| | - Martin B Dorner
- Biological Toxins, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Seestrasse 10, 13353 Berlin, Germany.
| |
Collapse
|
5
|
Electrochemical impedance spectroscopy biosensor for detection of active botulinum neurotoxin. SENSING AND BIO-SENSING RESEARCH 2014. [DOI: 10.1016/j.sbsr.2014.08.002] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
6
|
Banerjee P, Kintzios S, Prabhakarpandian B. Biotoxin detection using cell-based sensors. Toxins (Basel) 2013; 5:2366-83. [PMID: 24335754 PMCID: PMC3873691 DOI: 10.3390/toxins5122366] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2013] [Revised: 11/22/2013] [Accepted: 11/25/2013] [Indexed: 12/11/2022] Open
Abstract
Cell-based biosensors (CBBs) utilize the principles of cell-based assays (CBAs) by employing living cells for detection of different analytes from environment, food, clinical, or other sources. For toxin detection, CBBs are emerging as unique alternatives to other analytical methods. The main advantage of using CBBs for probing biotoxins and toxic agents is that CBBs respond to the toxic exposures in the manner related to actual physiologic responses of the vulnerable subjects. The results obtained from CBBs are based on the toxin-cell interactions, and therefore, reveal functional information (such as mode of action, toxic potency, bioavailability, target tissue or organ, etc.) about the toxin. CBBs incorporate both prokaryotic (bacteria) and eukaryotic (yeast, invertebrate and vertebrate) cells. To create CBB devices, living cells are directly integrated onto the biosensor platform. The sensors report the cellular responses upon exposures to toxins and the resulting cellular signals are transduced by secondary transducers generating optical or electrical signals outputs followed by appropriate read-outs. Examples of the layout and operation of cellular biosensors for detection of selected biotoxins are summarized.
Collapse
Affiliation(s)
- Pratik Banerjee
- Division of Epidemiology, Biostatistics, and Environmental Health, School of Public Health, The University of Memphis, 338 Robison Hall, 3825 Desoto Avenue, Memphis, TN 38152, USA
| | - Spyridon Kintzios
- School of Food Science, Biotechnology and Development, Faculty of Biotechnology, Agricultural University of Athens, Iera Odos 75, Athens 11855, Greece; E-Mail:
| | - Balabhaskar Prabhakarpandian
- Bioengineering Laboratory Core, Cellular and Biomolecular Engineering, CFD Research Corporation, 701 McMillian Way NW, Huntsville, AL 35806, USA; E-Mail:
| |
Collapse
|
7
|
Halliwell J, Gwenin C. A label free colorimetric assay for the detection of active botulinum neurotoxin type A by SNAP-25 conjugated colloidal gold. Toxins (Basel) 2013; 5:1381-91. [PMID: 23925142 PMCID: PMC3760041 DOI: 10.3390/toxins5081381] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2013] [Revised: 07/26/2013] [Accepted: 07/30/2013] [Indexed: 01/09/2023] Open
Abstract
Botulinum neurotoxins are one of the most potent toxins known to man. Current methods of detection involve the quantification of the toxin but do not take into account the percentage of the toxin that is active. At present the assay used for monitoring the activity of the toxin is the mouse bioassay, which is lengthy and has ethical issues due to the use of live animals. This report demonstrates a novel assay that utilises the endopeptidase activity of the toxin to detect Botulinum neurotoxin in a pharmaceutical sample. The cleaving of SNAP-25 is monitored via UV-Visible spectroscopy with a limit of detection of 373 fg/mL and has been further developed into a high throughput method using a microplate reader detecting down to 600 fg/mL of active toxin. The results show clear differences between the toxin product and the placebo, which contains the pharmaceutical excipients human serum albumin and lactose, showing that the assay detects the active form of the toxin.
Collapse
Affiliation(s)
| | - Christopher Gwenin
- Author to whom correspondence should be addressed; E-Mail: ; Tel: +44-1248-383-741; Fax: +44-1248-370-528
| |
Collapse
|
8
|
Bar-Or D, Slone DS, Mains CW, Rael LT. Dipeptidyl peptidase IV activity in commercial solutions of human serum albumin. Anal Biochem 2013; 441:13-7. [PMID: 23770236 DOI: 10.1016/j.ab.2013.06.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2013] [Revised: 05/14/2013] [Accepted: 06/06/2013] [Indexed: 11/15/2022]
Abstract
Due to the heterogeneous nature of commercial human serum albumin (cHSA), other components, such as the protease dipeptidyl peptidase IV (DPP-IV), possibly contribute to the therapeutic effect of cHSA. Here, we provide evidence for the first time that DPP-IV activity contributes to the formation of aspartate-alanine diketopiperazine (DA-DKP), a known immunomodulatory molecule from the N terminus of human albumin. cHSA was assayed for DPP-IV activity using a specific DPP-IV substrate and inhibitor. DPP-IV activity was assayed at 37 and 60°C because cHSA solutions are pasteurized at 60°C. DPP-IV activity in cHSA was compared with other sources of albumin such as a recombinant albumin (rHSA). In addition, the production of DA-DKP was measured by negative electrospray ionization/liquid chromatography mass spectrometry (ESI(-)/LCMS). Significant levels of DPP-IV activity were present in cHSA. This activity was abolished using a specific DPP-IV inhibitor. Fully 70 to 80% DPP-IV activity remained at 60°C compared with the 37°C incubate. No DPP-IV activity was present in rHSA, suggesting that DPP-IV activity is present only in HSA produced using the Cohn fractionation process. The formation of DA-DKP at 60°C was observed with the DPP-IV inhibitor significantly decreasing this formation. DPP-IV activity in cHSA results in the production of DA-DKP, which could account for some of the clinical effects of cHSA.
Collapse
Affiliation(s)
- David Bar-Or
- Trauma Research Laboratory, Swedish Medical Center, Englewood, CO 80113, USA.
| | | | | | | |
Collapse
|
9
|
Pellett S. Progress in cell based assays for botulinum neurotoxin detection. Curr Top Microbiol Immunol 2013; 364:257-85. [PMID: 23239357 DOI: 10.1007/978-3-642-33570-9_12] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Botulinum neurotoxins (BoNTs) are the most potent human toxins known and the causative agent of botulism, and are widely used as valuable pharmaceuticals. The BoNTs are modular proteins consisting of a heavy chain and a light chain linked by a disulfide bond. Intoxication of neuronal cells by BoNTs is a multi-step process including specific cell binding, endocytosis, conformational change in the endosome, translocation of the enzymatic light chain into the cells cytosol, and SNARE target cleavage. The quantitative and reliable potency determination of fully functional BoNTs produced as active pharmaceutical ingredient (API) requires an assay that considers all steps in the intoxication pathway. The in vivo mouse bioassay has for years been the 'gold standard' assay used for this purpose, but it requires the use of large numbers of mice and thus causes associated costs and ethical concerns. Cell-based assays are currently the only in vitro alternative that detect fully functional BoNTs in a single assay and have been utilized for years for research purposes. Within the last 5 years, several cell-based BoNT detection assays have been developed that are able to quantitatively determine BoNT potency with similar or greater sensitivity than the mouse bioassay. These assays now offer an alternative method for BoNT potency determination. Such quantitative and reliable BoNT potency determination is a crucial step in basic research, in the development of pharmaceutical BoNTs, and in the quantitative detection of neutralizing antibodies.
Collapse
Affiliation(s)
- Sabine Pellett
- Department of Bacteriology, University of Wisconsin, Madison, WI 53706, USA.
| |
Collapse
|
10
|
Lorenc ZP, Kenkel JM, Fagien S, Hirmand H, Nestor MS, Sclafani AP, Sykes JM, Waldorf HA. IncobotulinumtoxinA in clinical literature. Aesthet Surg J 2013; 33:23S-34S. [PMID: 23515196 DOI: 10.1177/1090820x12474635] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
IncobotulinumtoxinA is the third neurotoxin type A to be approved for aesthetic use in the United States. Because incobotulinumtoxinA has been in use in Europe for some time, the clinical literature is fairly replete with references to its properties and characteristics, as well as its safety and efficacy. In North America, 2 pivotal trials, referred to as GL-1 and GL-2, investigated the safety and efficacy of incobotulinumtoxinA in the glabellar region; both are currently in press with another journal. Other published studies of incobotulinumtoxinA are also described in depth in this article, including reports on aesthetic indications, diffusion, therapeutic indications, and studies pertaining to the preclinical and clinical pharmacology of incobotulinumtoxinA. Topics addressed include potency variability, mean concentration, stability and dissociation, and endopeptide immunoassay.
Collapse
|
11
|
Zhang LJ, Xue YQ, Yang C, Yang WH, Chen L, Zhang QJ, Qu TY, Huang S, Zhao LR, Wang XM, Duan WM. Human albumin prevents 6-hydroxydopamine-induced loss of tyrosine hydroxylase in in vitro and in vivo. PLoS One 2012; 7:e41226. [PMID: 22815976 PMCID: PMC3398951 DOI: 10.1371/journal.pone.0041226] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2012] [Accepted: 06/19/2012] [Indexed: 11/19/2022] Open
Abstract
Human albumin has recently been demonstrated to protect brain neurons from injury in rat ischemic brain. However, there is no information available about whether human albumin can prevent loss of tyrosine hydroxylase (TH) expression of dopaminergic (DA) neurons induced by 6-hydroxydopamine (6-OHDA) toxicity that is most commonly used to create a rat model of Parkinson's disease (PD). In the present study, two microliters of 1.25% human albumin were stereotaxically injected into the right striatum of rats one day before or 7 days after the 6-OHDA lesion in the same side. D-Amphetamine-induced rotational asymmetry was measured 7 days, 3 and 10 weeks after 6-OHDA lesion. We observed that intrastriatal administration of human albumin significantly reduced the degree of rotational asymmetry. The number of TH-immunoreactive neurons present in the substantia nigra was greater in 6-OHDA lesioned rats following human albumin-treatment than non-human albumin treatment. TH-immunoreactivity in the 6-OHDA-lesioned striatum was also significantly increased in the human albumin-treated rats. To examine the mechanisms underlying the effects of human albumin, we challenged PC12 cells with 6-OHDA as an in vitro model of PD. Incubation with human albumin prevented 6-OHDA-induced reduction of cell viability in PC12 cell cultures, as measured by MTT assay. Furthermore, human albumin reduced 6-OHDA-induced formation of reactive oxygen species (ROS) and apoptosis in cultured PC12 cells, as assessed by flow cytometry. Western blot analysis showed that human albumin inhibited 6-OHDA-induced activation of JNK, c-Jun, ERK, and p38 mitogen-activated protein kinases (MAPK) signaling in PC12 cultures challenged with 6-OHDA. Human albumin may protect against 6-OHDA toxicity by influencing MAPK pathway followed by anti-ROS formation and anti-apoptosis.
Collapse
Affiliation(s)
- Li-Juan Zhang
- Department of Anatomy, Capital Medical University, Beijing, China
- Department of Physiology, Capital Medical University, Beijing, China
| | - Yue-Qiang Xue
- Department of Cellular Biology and Anatomy, Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States of America
| | - Chun Yang
- Department of Anatomy, Capital Medical University, Beijing, China
| | - Wei-Hua Yang
- Department of Anatomy, Capital Medical University, Beijing, China
| | - Long Chen
- Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States of America
| | - Qian-Jin Zhang
- Department of Biology, Xavier University of Louisiana, New Orleans, Louisiana, United States of America
| | - Ting-Yu Qu
- Department of Psychiatry, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, United States of America
| | - Shile Huang
- Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States of America
| | - Li-Ru Zhao
- Department of Neurology, Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States of America
| | - Xiao-Min Wang
- Department of Physiology, Capital Medical University, Beijing, China
- * E-mail: (WMD); (XMW)
| | - Wei-Ming Duan
- Department of Anatomy, Capital Medical University, Beijing, China
- * E-mail: (WMD); (XMW)
| |
Collapse
|
12
|
|
13
|
Dorner MB, Schulz KM, Kull S, Dorner BG. Complexity of Botulinum Neurotoxins: Challenges for Detection Technology. Curr Top Microbiol Immunol 2012. [DOI: 10.1007/978-3-662-45790-0_11] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|